Sarepta's Stance on Elevidys - Search News

News

Sarepta, Elevidys and FDA

Invezz on MSN · 23h

Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments

Sarepta Therapeutics shares jumped over 36% in premarket trading on Tuesday after the company said it had received US Food and Drug Administration (FDA) approval to restart shipments of its flagship gene therapy Elevidys in the United States.

Pharmaceutical Technology on M… · 1d

Sarepta allowed to continue US Elevidys shipments

It has been a tumultuous two weeks for Sarepta; however, the FDA reauthorising US shipments of Elevidys will be a welcome development.

The Boston Globe · 14h

Sarepta soars after FDA says some patients can get Elevidys

Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again.

23h

Sarepta: SRPT Stock To $40?

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results